Chardan Capital Reiterates “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Chardan Capital restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report report published on Thursday morning,Benzinga reports. Chardan Capital currently has a $7.00 target price on the stock.

Several other equities analysts have also recently weighed in on TSHA. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group reduced their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $2.06 on Thursday. The company has a quick ratio of 5.22, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The company has a market capitalization of $422.18 million, a PE ratio of 3.27 and a beta of 0.44. The firm’s 50 day moving average is $1.98 and its 200-day moving average is $2.38.

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in Taysha Gene Therapies in the third quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares in the last quarter. Privium Fund Management B.V. boosted its holdings in shares of Taysha Gene Therapies by 21.8% during the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock worth $241,000 after buying an additional 21,500 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $48,000. Finally, Artal Group S.A. boosted its holdings in shares of Taysha Gene Therapies by 0.7% during the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after buying an additional 24,444 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.